|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Schnelldorfer T, Ware AL, Sarr MG, Smyrk
TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM and
Farnell MB: Long-term survival after pancreatoduodenectomy for
pancreatic adenocarcinoma: Is cure possible? Ann Surg. 247:456–462.
2008.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Al-Hawary MM, Kaza RK, Wasnik AP and
Francis IR: Staging of pancreatic cancer: Role of imaging. Semin
Roentgenol. 48:245–252. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Neoptolemos JP, Stocken DD, Friess H,
Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C,
Lacaine F, et al: A randomized trial of chemoradiotherapy and
chemotherapy after resection of pancreatic cancer. N Engl J Med.
350:1200–1210. 2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hsu CP, Hsu JT, Liao CH, Kang SC, Lin BC,
Hsu YP, Yeh CN, Yeh TS and Hwang TL: Three-year and five-year
outcomes of surgical resection for pancreatic ductal
adenocarcinoma: Long-term experiences in one medical center. Asian
J Surg. 41:115–123. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Andrén-Sandberg A and Neoptolemos JP:
Resection for pancreatic cancer in the new millennium.
Pancreatology. 2:431–439. 2002.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Conroy T, Castan F, Lopez A, Turpin A, Ben
Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, et al:
Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy
for pancreatic cancer: A randomized clinical trial. JAMA Oncol.
8:1571–1578. 2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Seufferlein T, Uhl W, Kornmann M, Algül H,
Friess H, König A, Ghadimi M, Gallmeier E, Bartsch DK, Lutz MP, et
al: Perioperative or only adjuvant gemcitabine plus nab-paclitaxel
for resectable pancreatic cancer (NEONAX)-a randomized phase II
trial of the AIO pancreatic cancer group. Ann Oncol. 34:91–100.
2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ahmad SA, Duong M, Sohal DPS, Gandhi NS,
Beg MS, Wang-Gillam A, Wade JL III, Chiorean EG, Guthrie KA, Lowy
AM, et al: Surgical outcome results from SWOG S1505: A randomized
clinical trial of mFOLFIRINOX versus gemcitabine/nab-paclitaxel for
perioperative treatment of resectable pancreatic ductal
adenocarcinoma. Ann Surg. 272:481–486. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Labori KJ, Bratlie SO, Biörserud C,
Bjornsson B, Bringeland E, Elander N, Grønbech JK, Haux J,
Hemmingsson O, Nymo L, et al: Short-course neoadjuvant FOLFIRINOX
versus upfront surgery for resectable pancreatic head cancer: A
multicenter randomized phase-II trial (NORPACT-1). J Clin Oncol.
41(LBA4005)2023.
|
|
11
|
Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi
S, Sho M, Honda G, Matsumoto I, Wada K, Furuse J, et al: Randomized
phase II/III trial of neoadjuvant chemotherapy with gemcitabine and
S-1 versus upfront surgery for resectable pancreatic cancer
(Prep-02/JSAP05). Jpn J Clin Oncol. 49:190–194. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kitano Y, Inoue Y, Takeda T, Oba A, Ono Y,
Sato T, Ito H, Ozaka M, Sasaki T, Sasahira N, et al: Clinical
efficacy of neoadjuvant chemotherapy with gemcitabine plus S-1 for
resectable pancreatic ductal adenocarcinoma compared with upfront
surgery. Ann Surg Oncol. 30:5093–5102. 2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Liu S, Li H, Xue Y and Yang L: Prognostic
value of neoadjuvant therapy for resectable and borderline
resectable pancreatic cancer: A meta-analysis of randomized
controlled trials. PLoS One. 18(e0290888)2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Allen VB, Gurusamy KS, Takwoingi Y, Kalia
A and Davidson BR: Diagnostic accuracy of laparoscopy following
computed tomography (CT) scanning for assessing the resectability
with curative intent in pancreatic and periampullary cancer.
Cochrane Database Syst Rev. 7(CD009323)2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hashimoto D, Chikamoto A, Sakata K,
Nakagawa S, Hayashi H, Ohmuraya M, Hirota M, Yoshida N, Beppu T and
Baba H: Staging laparoscopy leads to rapid induction of
chemotherapy for unresectable pancreatobiliary cancers. Asian J
Endosc Surg. 8:59–62. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sell NM, Fong ZV, Del Castillo CF, Qadan
M, Warshaw AL, Chang D, Lillemoe KD and Ferrone CR: Staging
laparoscopy not only saves patients an incision, but may also help
them live longer. Ann Surg Oncol. 25:1009–1016. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Japan Pancreatic Society, General rules
for the pancreatic cancer, the 8th edition Kanehara & Co.,
Ltd., Tokyo, 2023.
|
|
18
|
Evans DB, Rich TA, Byrd DR, Cleary KR,
Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ and Ames FC:
Preoperative chemoradiation and pancreaticoduodenectomy for
adenocarcinoma of the pancreas. Arch Surg. 127:1335–1339.
1992.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ushimaru Y, Fujiwara Y, Shishido Y, Omori
T, Yanagimoto Y, Sugimura K, Moon JH, Miyata H and Yano M:
Condition mimicking peritoneal metastasis associated with
preoperative staging laparoscopy in advanced gastric cancer. Asian
J Endosc Surg. 12:457–460. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Katz MHG, Petroni GR, Bauer T, Reilley MJ,
Wolpin BM, Stucky CC, Bekaii-Saab TS, Elias R, Merchant N, Dias
Costa A, et al: Multicenter randomized controlled trial of
neoadjuvant chemoradiotherapy alone or in combination with
pembrolizumab in patients with resectable or borderline resectable
pancreatic adenocarcinoma. J Immunother Cancer.
11(e007586)2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Van Dam JL, Verkolf EMM, Dekker EN,
Bonsing BA, Bratlie SO, Brosens LAA, Busch OR, van Driel LMJW, van
Eijck CHJ, Feshtali S, et al: Perioperative or adjuvant mFOLFIRINOX
for resectable pancreatic cancer (PREOPANC-3): Study protocol for a
multicenter randomized controlled trial. BMC Cancer.
23(728)2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Stefanidis D, Grove KD, Schwesinger WH and
Thomas CR Jr: The current role of staging laparoscopy for
adenocarcinoma of the pancreas: A review. Ann Oncol. 17:189–199.
2006.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Karabicak I, Satoi S, Yanagimoto H,
Yamamoto T, Hirooka S, Yamaki S, Kosaka H, Inoue K, Matsui Y and
Kon M: Risk factors for latent distant organ metastasis detected by
staging laparoscopy in patients with radiologically defined locally
advanced pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat
Sci. 23:750–755. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
24
|
Pisters PW, Lee JE, Vauthey JN,
Charnsangavej C and Evans DB: Laparoscopy in the staging of
pancreatic cancer. Br J Surg. 88:325–337. 2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Camacho D, Reichenbach D, Duerr GD, Venema
TL, Sweeney JF and Fisher WE: Value of laparoscopy in the staging
of pancreatic cancer. JOP. 6:552–561. 2005.PubMed/NCBI
|
|
26
|
Peng JS, Mino J, Monteiro R, Morris-Stiff
G, Ali NS, Wey J, El-Hayek KM, Walsh RM and Chalikonda S:
Diagnostic laparoscopy prior to neoadjuvant therapy in pancreatic
cancer is high yield: An analysis of outcomes and costs. J
Gastrointest Surg. 21:1420–1427. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Morris S, Gurusamy KS, Sheringham J and
Davidson BR: Cost-effectiveness of diagnostic laparoscopy for
assessing resectability in pancreatic and periampullary cancer. BMC
Gastroenterol. 15(44)2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yamaguchi K, Okusaka T, Shimizu K, Furuse
J, Ito Y, Hanada K, Shimosegawa T and Okazaki K: Committee for
Revision of Clinical Guidelines for Pancreatic Cancer of the Japan
Pancreas Society. clinical practice guidelines for pancreatic
cancer 2016 from the Japan pancreas society: A synopsis. Pancreas.
46:595–604. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
De Rosa A, Cameron IC and Gomez D:
Indications for staging laparoscopy in pancreatic cancer. HPB
(Oxford). 18:13–20. 2016.PubMed/NCBI View Article : Google Scholar
|
